Functional characterization of the 19q12 amplicon in grade III breast cancers

Breast Cancer Research

Table 1 19q12 amplification in 313 breast cancers and clinicopathological associations

		19q12 Amp n (%)	19q12 Not amp n (%)	P-value	CCNE1 Amp (%)	CCNE1 Not amp (%)	P-value
Whole cohort		16 (5.1%)	297 (94.9%)	NA	5 (1.6%)	308 (98.4%)	NA
Histological grade*				0.0018 ⁺			0.1693⁺
	I/II	0 (0%)	109 (100%)		0 (0%)	109 (100%)
	III	16 (8%)	188 (92%)		5 (2%)	199 (98%)
ER				0.0042 ⁺			0.01984 ⁺
	Positive	3 (2%)	166 (98%)		0 (0%)	169 (100%)
	Negative	13 (9%)	131 (91%)		5 (3.5%)	139 (96.5%)
HER2				0.5398⁺			0.9801⁺
	Positive	2 (3%)	62 (97%)		1(1.6%)	63(98.4%)
	Negative	14 (6%)	235 (94%)		4(1.6%)	245(98.4%)
Subtypes				0.0056^**			0.0500^**
	ER-/HER2-	11 (11%)	90 (89%)	0.0024***	4 (4%)	97 (96%)	0.0399***
	HER2	2 (3%)	62 (97%)		1 (2%)	63 (98%)
	ER+/HER2-	3 (2%)	145 (98%)		0 (0%)	148 (100%)

Amp, amplified; CCNE1, cyclin E1; ER, oestrogen receptor; NA, not applicable; Not amp, not amplified.
*Histological grade determined by the modified Scarff-Bloom-Richardson system [32].
Significant P-values are highlighted in bold.
+: Fisher's exact test
**: Chi-square test
***: Comparison between ER-/HER2- vs the remaining subtypes by Fisher's exact test.
^: Given that > 20% of the groups have n < 5, the Chi-square P-value should be interpreted with caution.

ISSN: 1465-542X